托珠单抗治疗COVID-19住院患者细胞因子释放综合征的生存与临床结局
这项观察性研究纳入2020年3月10日至3月31日住院的239例COVID-19患者,按靶向CRS算法使用托珠单抗。重症患者生存率较低且需机械通气比例更高。托珠单抗治疗患者氧合和炎症标志物改善,生存率高于预期,但需随机试验证实。
要点
- 重症COVID-19患者生存率显著低于非重症(78% vs 93%)。
- 托珠单抗治疗患者氧合和炎症标志物改善,生存率较高。
- 需随机试验确认托珠单抗对COVID-19的获益。
核心结论
- 包含托珠单抗靶向CRS的治疗算法可能影响机械通气和生存结局。
- 托珠单抗治疗患者氧合和炎症标志物改善,生存率高于预期。
- 需随机试验证实这些发现。
研究设计与样本
- 回顾性观察性研究,纳入2020年3月10日至3月31日住院的连续COVID-19患者239例,随访至2020年4月21日。
- 根据入院时疾病严重程度(严重:需≥3 L/min supplemental oxygen to maintain SpO2 >93%)分层。
- 托珠单抗治疗患者进行前后临床反应、生物标志物和安全性分析。
主要发现
- 重症患者生存率78% vs 非重症93%(P < .001),需机械通气比例44% vs 5%(P < .001),中位机械通气天数5.5 vs 1.0(P = .003)。
- 托珠单抗治疗患者153例(64%),其中90%为重症;非重症中44%因进展性CRS接受托珠单抗。
- 重症托珠单抗治疗患者入院高敏C反应蛋白较高(120 vs 71 mg/L;P < .001),更早接受托珠单抗(2 vs 3天;P < .001),但生存率与非重症相似(83% vs 91%;P = .11)。
- 需机械通气的托珠单抗治疗患者生存率75%(95% CI,64-89)。
- 托珠单抗治疗后不良事件少,氧合和炎症标志物改善,但D-二聚体和可溶性IL-2受体水平显著升高。
临床怎么用
- 对COVID-19住院患者可考虑使用靶向CRS的托珠单抗治疗算法,但需随机试验确认。
- 治疗中需监测D-二聚体和可溶性IL-2受体水平变化。
局限性
- 为观察性研究,存在混杂因素,不能确立因果关系。
- 需随机试验证实托珠单抗的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tocilizumab, an IL-6 receptor antagonist, can be used to treat cytokine release syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) case series. RESEARCH QUESTION: The goal of this study was to determine if tocilizumab benefits patients hospitalized with COVID-19. STUDY DESIGN AND METHODS: This observational study of consecutive COVID-19 patients hospitalized between March 10, 2020, and March 31, 2020, and followed up through April 21, 2020, was conducted by chart review. Patients were treated with tocilizumab using an algorithm that targeted CRS. Survival and mechanical ventilation (MV) outcomes were reported for 14 days and stratified according to disease severity designated at admission (severe, ≥ 3 L supplemental oxygen to maintain oxygen saturation > 93%). For tocilizumab-treated patients, pre/post analyses of clinical response, biomarkers, and safety outcomes were assessed. Post hoc survival analyses were conducted for race/ethnicity. RESULTS: Among the 239 patients, median age was 64 years; 36% and 19% were black and Hispanic, respectively. Hospital census increased exponentially, yet MV census did not. Severe disease was associated with lower survival (78% vs 93%; P < .001), greater proportion requiring MV (44% vs 5%; P < .001), and longer median MV days (5.5 vs 1.0; P = .003). Tocilizumab-treated patients (n = 153 [64%]) comprised 90% of those with severe disease; 44% of patients with nonsevere disease received tocilizumab for evolving CRS. Tocilizumab-treated patients with severe disease had higher admission levels of high-sensitivity C-reactive protein (120 vs 71 mg/L; P < .001) and received tocilizumab sooner (2 vs 3 days; P < .001), but their survival was similar to that of patients with nonsevere disease (83% vs 91%; P = .11). For tocilizumab-treated patients requiring MV, survival was 75% (95% CI, 64-89). Following tocilizumab treatment, few adverse events occurred, and oxygenation and inflammatory biomarkers (eg, high-sensitivity C-reactive protein, IL-6) improved; however, D-dimer and soluble IL-2 receptor (also termed CD25) levels increased significantly. Survival in black and Hispanic patients, after controlling for age, was significantly higher than in white patients (log-rank test, P = .002). INTERPRETATION: A treatment algorithm that included tocilizumab to target CRS may influence MV and survival outcomes. In tocilizumab-treated patients, oxygenation and inflammatory biomarkers improved, with higher than expected survival. Randomized trials must confirm these findings.
引用
- Price CC, Altice FL, Shyr Y, et al. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest. 2020. PMID: 32553536. doi:10.1016/j.chest.2020.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。